UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma
Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL. [Display omitted] •Useful UHPLC–MS/MS method to quantify a wide panel of antiretroviral drugs.•Validated method following FDA guidelines.•Fast and cheap protein precipitation...
Saved in:
Published in | Journal of pharmaceutical and biomedical analysis Vol. 138; pp. 223 - 230 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier B.V
10.05.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL.
[Display omitted]
•Useful UHPLC–MS/MS method to quantify a wide panel of antiretroviral drugs.•Validated method following FDA guidelines.•Fast and cheap protein precipitation protocol, suitable for clinical routine.•The method has been tested on real-life specimens with good results.
Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs.
In this work, we describe the development and validation of a new UPLC–MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma.
One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs.
The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC–MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG. |
---|---|
AbstractList | Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC-MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC-MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG.Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC-MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC-MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG. Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL. [Display omitted] •Useful UHPLC–MS/MS method to quantify a wide panel of antiretroviral drugs.•Validated method following FDA guidelines.•Fast and cheap protein precipitation protocol, suitable for clinical routine.•The method has been tested on real-life specimens with good results. Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC–MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC–MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG. Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC-MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC-MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG. |
Author | D’Avolio, Antonio Simiele, Marco Ariaudo, Alessandra Carcieri, Chiara Bonora, Stefano De Nicolò, Amedeo Favata, Fabio Ferrante, Martina Di Perri, Giovanni |
Author_xml | – sequence: 1 givenname: Marco surname: Simiele fullname: Simiele, Marco organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 2 givenname: Alessandra surname: Ariaudo fullname: Ariaudo, Alessandra organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 3 givenname: Amedeo surname: De Nicolò fullname: De Nicolò, Amedeo email: amedeo.denicolo@unito.it organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 4 givenname: Fabio surname: Favata fullname: Favata, Fabio organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 5 givenname: Martina surname: Ferrante fullname: Ferrante, Martina organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 6 givenname: Chiara surname: Carcieri fullname: Carcieri, Chiara organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 7 givenname: Stefano surname: Bonora fullname: Bonora, Stefano organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 8 givenname: Giovanni surname: Di Perri fullname: Di Perri, Giovanni organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy – sequence: 9 givenname: Antonio surname: D’Avolio fullname: D’Avolio, Antonio organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28219799$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UsuO0zAUtdAgpjPwAyyQlyyajO2ksSOxQRUvqSOQhpHYWY5z07pK7I7tFLHjH_hDFnwHTh-bWczKutfnnGufe67QhXUWEHpNSU4JrW62-XbXqJwRynPCckLYMzSjghcZq8ofF2hGeEEzTsTiEl2FsCWELGhdvkCXTDBa87qeoX_331bLv7__3N7d3N7hAeLGtbhzHscN4GCGsY_KghsDfhiVjaYzWkXjLHZdgngAbOEnnm48RO_2xqset35chzluXT9GWHuVunMM_d6cq0RosTf9zqTCWJgfGi7NnAYbHwHsY1G1BhsD3vXpLdo1RpsQVTwpRWcPuo1zIYIP2Fi8GQdlE16FQb1EzzvVB3h1Oq_R_ccP35efs9XXT1-W71eZLhmLWQVVrUpRQ82KmgIXrG00tLVSnFGoigWvuq5VTNQVobTlQlXAaSGaqtQKyq64Rm-PujvvHkYIUQ4maOj7o4kybYdUpRCEJOibE3RsBmjlzptB-V_yvJsEEEeA9i4ED53UJh7Mj16ZXlIipxjIrZxiIKcYSMJkikGiskfUs_qTpHdHEiSD9ga8DNqATf9Pa9BRts48Rf8PmObT9A |
CitedBy_id | crossref_primary_10_1093_jac_dky508 crossref_primary_10_1002_jssc_202100152 crossref_primary_10_1093_jat_bkaf016 crossref_primary_10_1111_bcp_15538 crossref_primary_10_2174_1573412914666180621110432 crossref_primary_10_1007_s10337_024_04314_2 crossref_primary_10_1186_s12981_021_00338_y crossref_primary_10_1002_sscp_202400168 crossref_primary_10_1111_bcp_13552 crossref_primary_10_1016_j_jpba_2019_113057 crossref_primary_10_1002_sscp_201800043 crossref_primary_10_1007_s40262_020_00916_9 crossref_primary_10_1007_s11696_019_00771_4 crossref_primary_10_15369_sujms_32_91 crossref_primary_10_1016_j_trac_2023_116964 crossref_primary_10_1134_S1061934821100129 crossref_primary_10_1016_j_jchromb_2024_124275 crossref_primary_10_1007_s40261_018_0739_9 crossref_primary_10_1371_journal_pone_0246994 crossref_primary_10_1002_bmc_4274 crossref_primary_10_1093_jac_dkae080 crossref_primary_10_1016_j_ijms_2020_116370 crossref_primary_10_3390_antiox14010082 crossref_primary_10_1002_slct_202203174 crossref_primary_10_1002_bmc_4170 crossref_primary_10_1093_jac_dkx461 crossref_primary_10_3390_molecules26082123 crossref_primary_10_3390_ph14010012 crossref_primary_10_53879_id_56_10_11796 crossref_primary_10_1016_j_talanta_2020_121862 crossref_primary_10_1080_10408347_2021_1908111 crossref_primary_10_1016_j_ijantimicag_2024_107200 crossref_primary_10_1080_10408347_2022_2039094 crossref_primary_10_1016_j_aca_2019_01_015 crossref_primary_10_1016_j_jchromb_2018_12_008 crossref_primary_10_3390_diagnostics13020295 crossref_primary_10_52711_0974_360X_2022_00893 crossref_primary_10_1556_1326_2018_00459 crossref_primary_10_1002_bmc_5708 crossref_primary_10_1080_10408347_2022_2080493 crossref_primary_10_1002_jssc_202201067 crossref_primary_10_1016_j_talanta_2018_01_012 crossref_primary_10_1016_j_diamond_2021_108332 crossref_primary_10_1016_j_cca_2023_117678 crossref_primary_10_1016_j_jpba_2020_113119 crossref_primary_10_1093_jac_dkaa094 crossref_primary_10_1016_j_jpba_2017_07_003 |
Cites_doi | 10.1002/bmc.2765 10.1016/j.jpba.2013.08.002 10.1016/S0140-6736(12)60918-0 10.1517/14740331003767395 10.1097/QAI.0b013e31824d006e 10.1097/00002030-200203001-00002 10.2152/jmi.60.35 10.1016/j.jpba.2013.02.025 10.1038/ijos.2013.76 10.1007/s40265-014-0256-y 10.1016/S0140-6736(12)60917-9 10.1097/FTD.0b013e318189596d 10.1002/jms.3200 10.1016/j.jchromb.2006.10.030 10.1007/s11904-014-0207-y 10.1016/j.jpba.2015.08.004 10.1016/j.jchromb.2010.03.036 |
ContentType | Journal Article |
Copyright | 2017 Copyright © 2017. Published by Elsevier B.V. |
Copyright_xml | – notice: 2017 – notice: Copyright © 2017. Published by Elsevier B.V. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.jpba.2017.02.002 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-264X |
EndPage | 230 |
ExternalDocumentID | 28219799 10_1016_j_jpba_2017_02_002 S0731708516314534 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM 9JN AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AATCM AAXUO ABFRF ABJNI ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADECG ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AFZHZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJSZI ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FLBIZ FNPLU FYGXN G-Q GBLVA IHE J1W KOM M34 M36 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG RNS ROL RPZ SCC SCH SDF SDG SDP SES SPC SPCBC SSK SSP SSZ T5K TEORI YK3 ~G- 29L 53G AAQXK AATTM AAXKI AAYWO AAYXX ABFNM ABWVN ABXDB ACNNM ACRPL ACVFH ADCNI ADMUD ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AHHHB AIGII AIIUN AJQLL AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CITATION FEDTE FGOYB G-2 HMT HMU HVGLF HZ~ R2- SCB SEW SPT SSH WUQ XPP CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
ID | FETCH-LOGICAL-c422t-6e69a489e92391e782dbced9aa721e63576ffda2896011d78a6e7138b64cae4f3 |
IEDL.DBID | .~1 |
ISSN | 0731-7085 1873-264X |
IngestDate | Tue Aug 05 11:03:17 EDT 2025 Wed Feb 19 02:00:02 EST 2025 Thu Apr 24 23:07:19 EDT 2025 Tue Jul 01 01:17:48 EDT 2025 Fri Feb 23 02:25:39 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Tandem mass spectrometry Antiretrovirals Liquid chromatography Reverse phase Protein precipitation HAART |
Language | English |
License | Copyright © 2017. Published by Elsevier B.V. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c422t-6e69a489e92391e782dbced9aa721e63576ffda2896011d78a6e7138b64cae4f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 28219799 |
PQID | 1870648800 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1870648800 pubmed_primary_28219799 crossref_citationtrail_10_1016_j_jpba_2017_02_002 crossref_primary_10_1016_j_jpba_2017_02_002 elsevier_sciencedirect_doi_10_1016_j_jpba_2017_02_002 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-05-10 |
PublicationDateYYYYMMDD | 2017-05-10 |
PublicationDate_xml | – month: 05 year: 2017 text: 2017-05-10 day: 10 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of pharmaceutical and biomedical analysis |
PublicationTitleAlternate | J Pharm Biomed Anal |
PublicationYear | 2017 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Younai (bib0005) 2013; 5 De Nicolò, Abdi, Boglione, Baiett, Allegra, Di Perri, D'Avolio (bib0115) 2015; 115 Djerada, Feliu, Tournois, Vautier, Binet, Robinet, Marty, Gozalo, Lamiable, Millart (bib0070) 2013; 86 FDA (bib0095) 2013 Bourgeois, Womack, Newsom, Caldwell (bib0015) 2012; 24 Back, Gatti, Fletcher, Garaffo, Haubrich, Hoetelmans, Kurowski, Luber, Merry, Perno (bib0045) 2002; 16 Sax, DeJesus, Mills, Zolopa, Cohen, Wohl, Gallant, Liu, Zhong, Yale, White, Kearney, Szwarcberg, Quirk, Cheng (bib0030) 2012; 379 Shibata, Takahashi, Yoshino, Kuwahara, Nomura, Yokomaku, Sugiura (bib0085) 2013; 60 Cohen, Molina, Cahn, Clotet, Fourie, Grinsztejn, Wu, Johnson, Saag, Supparatpinyo, Crauwels, Lefebvre, Rimsky, Vanveggel, Williams, Boven (bib0025) 2012; 60 Liu, Ma, Zhang (bib0050) 2010; 9 Aouri, Calmy, Hirschel, Telenti, Buclin, Cavassini, Rauch, Decosterd (bib0055) 2013; 48 McCormack (bib0040) 2014; 74 D'Avolio, Baietto, Siccardi, Sciandra, Simiele, Oddone, Bonora, Di Perri (bib0100) 2008; 30 EMA (bib0090) 2011 Svicher, Ceccherini-Silberstein, Antinori, Aquaro, Perno (bib0010) 2014; 11 Gupta, Guttikar, Patel, Shrivastav, Sanyal (bib0080) 2014 D'Avolio, De Nicolo, Agnesod, Simiele, Mohamed Abdi, Dilly Penchala, Boglione, Cariti, Di Perri (bib0110) 2013; 78–79 Ford, Lee, Andrieux-Meyer, Calmy (bib0020) 2011; 3 Burugula, Pilli, Makula, Lodagala, Kandhagatla (bib0065) 2012; 27 Else, Watson, Tjia, Hughes, Siccardi, Khoo, Back (bib0075) 2010; 878 DeJesus, Rockstroh, Henry, Molina, Gathe, Ramanathan, Wei, Yale, Szwarcberg, White, Cheng, Kearney (bib0035) 2012; 379 Bennetto-Hood, Tabolt, Savina, Acosta (bib0060) 2013; 945–946 D'Avolio, Sciandra, Siccardi, Baietto, de Requena, Bonora, Di Perri (bib0105) 2007; 848 Bourgeois (10.1016/j.jpba.2017.02.002_bib0015) 2012; 24 D'Avolio (10.1016/j.jpba.2017.02.002_bib0100) 2008; 30 Aouri (10.1016/j.jpba.2017.02.002_bib0055) 2013; 48 Gupta (10.1016/j.jpba.2017.02.002_bib0080) 2014 Ford (10.1016/j.jpba.2017.02.002_bib0020) 2011; 3 EMA (10.1016/j.jpba.2017.02.002_bib0090) 2011 Sax (10.1016/j.jpba.2017.02.002_bib0030) 2012; 379 FDA (10.1016/j.jpba.2017.02.002_bib0095) 2013 Djerada (10.1016/j.jpba.2017.02.002_bib0070) 2013; 86 Younai (10.1016/j.jpba.2017.02.002_bib0005) 2013; 5 Burugula (10.1016/j.jpba.2017.02.002_bib0065) 2012; 27 McCormack (10.1016/j.jpba.2017.02.002_bib0040) 2014; 74 Else (10.1016/j.jpba.2017.02.002_bib0075) 2010; 878 Shibata (10.1016/j.jpba.2017.02.002_bib0085) 2013; 60 Cohen (10.1016/j.jpba.2017.02.002_bib0025) 2012; 60 Svicher (10.1016/j.jpba.2017.02.002_bib0010) 2014; 11 DeJesus (10.1016/j.jpba.2017.02.002_bib0035) 2012; 379 Bennetto-Hood (10.1016/j.jpba.2017.02.002_bib0060) 2013; 945–946 Liu (10.1016/j.jpba.2017.02.002_bib0050) 2010; 9 D'Avolio (10.1016/j.jpba.2017.02.002_bib0110) 2013; 78–79 De Nicolò (10.1016/j.jpba.2017.02.002_bib0115) 2015; 115 D'Avolio (10.1016/j.jpba.2017.02.002_bib0105) 2007; 848 Back (10.1016/j.jpba.2017.02.002_bib0045) 2002; 16 |
References_xml | – volume: 379 start-page: 2429 year: 2012 end-page: 2438 ident: bib0035 article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 non-inferiority trial publication-title: Lancet – volume: 60 start-page: 33 year: 2012 end-page: 42 ident: bib0025 article-title: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials publication-title: J. Acquir. Immune Defic. Syndr. – volume: 27 start-page: 172 year: 2012 end-page: 178 ident: bib0065 article-title: Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma publication-title: Biomed. Chromatogr. – volume: 11 start-page: 186 year: 2014 end-page: 194 ident: bib0010 article-title: Understanding HIV compartments and reservoirs publication-title: Curr. HIV/AIDS Rep. – volume: 878 start-page: 1455 year: 2010 end-page: 1465 ident: bib0075 article-title: Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – year: 2011 ident: bib0090 article-title: Guideline on Bioanalytical Method Validation – volume: 848 start-page: 374 year: 2007 end-page: 378 ident: bib0105 article-title: A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – year: 2013 ident: bib0095 article-title: Guidance for Industry: Bioanalytical Method Validation – volume: 74 start-page: 1241 year: 2014 end-page: 1252 ident: bib0040 article-title: Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults publication-title: Drugs – volume: 115 start-page: 443 year: 2015 end-page: 449 ident: bib0115 article-title: UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells publication-title: J. Pharm. Biomed. Anal. – volume: 3 start-page: 35 year: 2011 end-page: 44 ident: bib0020 article-title: Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings publication-title: HIV AIDS (Auckl) – volume: 379 start-page: 2439 year: 2012 end-page: 2448 ident: bib0030 article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks publication-title: Lancet – volume: 5 start-page: 191 year: 2013 end-page: 199 ident: bib0005 article-title: Thirty years of the human immunodeficiency virus epidemic and beyond publication-title: Int. J. Oral Sci. – volume: 48 start-page: 616 year: 2013 end-page: 625 ident: bib0055 article-title: A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients publication-title: J. Mass Spectrom. – volume: 60 start-page: 35 year: 2013 end-page: 40 ident: bib0085 article-title: Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations publication-title: J. Med. Invest. – volume: 86 start-page: 100 year: 2013 end-page: 111 ident: bib0070 article-title: Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology publication-title: J. Pharm. Biomed. Anal. – volume: 78–79 start-page: 217 year: 2013 end-page: 223 ident: bib0110 article-title: A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir publication-title: J. Pharm. Biomed. Anal. – volume: 24 start-page: 12 year: 2012 end-page: 15 ident: bib0015 article-title: A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing publication-title: HIV Clin. – volume: 30 start-page: 662 year: 2008 end-page: 669 ident: bib0100 article-title: An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients publication-title: Ther. Drug Monit. – volume: 945–946 start-page: 225 year: 2013 end-page: 232 ident: bib0060 article-title: A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – volume: 16 start-page: S5 year: 2002 end-page: 37 ident: bib0045 article-title: Therapeutic drug monitoring in HIV infection: current status and future directions publication-title: AIDS – year: 2014 ident: bib0080 article-title: Reliable LC-MS/MS assay for the estimation of rilpivirine in human plasma: application to a bioequivalence study and incurred sample reanalysis publication-title: Drug Test Anal – volume: 9 start-page: 743 year: 2010 end-page: 758 ident: bib0050 article-title: Therapeutic drug monitoring in highly active antiretroviral therapy publication-title: Expert Opin. Drug Saf. – volume: 27 start-page: 172 year: 2012 ident: 10.1016/j.jpba.2017.02.002_bib0065 article-title: Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma publication-title: Biomed. Chromatogr. doi: 10.1002/bmc.2765 – volume: 86 start-page: 100 year: 2013 ident: 10.1016/j.jpba.2017.02.002_bib0070 article-title: Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2013.08.002 – volume: 379 start-page: 2429 year: 2012 ident: 10.1016/j.jpba.2017.02.002_bib0035 publication-title: Lancet doi: 10.1016/S0140-6736(12)60918-0 – volume: 9 start-page: 743 year: 2010 ident: 10.1016/j.jpba.2017.02.002_bib0050 article-title: Therapeutic drug monitoring in highly active antiretroviral therapy publication-title: Expert Opin. Drug Saf. doi: 10.1517/14740331003767395 – volume: 60 start-page: 33 year: 2012 ident: 10.1016/j.jpba.2017.02.002_bib0025 article-title: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials publication-title: J. Acquir. Immune Defic. Syndr. doi: 10.1097/QAI.0b013e31824d006e – year: 2013 ident: 10.1016/j.jpba.2017.02.002_bib0095 – volume: 16 start-page: S5 issue: Suppl. 1 year: 2002 ident: 10.1016/j.jpba.2017.02.002_bib0045 article-title: Therapeutic drug monitoring in HIV infection: current status and future directions publication-title: AIDS doi: 10.1097/00002030-200203001-00002 – volume: 60 start-page: 35 year: 2013 ident: 10.1016/j.jpba.2017.02.002_bib0085 article-title: Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations publication-title: J. Med. Invest. doi: 10.2152/jmi.60.35 – year: 2014 ident: 10.1016/j.jpba.2017.02.002_bib0080 article-title: Reliable LC-MS/MS assay for the estimation of rilpivirine in human plasma: application to a bioequivalence study and incurred sample reanalysis publication-title: Drug Test Anal – volume: 78–79 start-page: 217 year: 2013 ident: 10.1016/j.jpba.2017.02.002_bib0110 article-title: A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2013.02.025 – volume: 5 start-page: 191 year: 2013 ident: 10.1016/j.jpba.2017.02.002_bib0005 article-title: Thirty years of the human immunodeficiency virus epidemic and beyond publication-title: Int. J. Oral Sci. doi: 10.1038/ijos.2013.76 – volume: 24 start-page: 12 year: 2012 ident: 10.1016/j.jpba.2017.02.002_bib0015 article-title: A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing publication-title: HIV Clin. – volume: 3 start-page: 35 year: 2011 ident: 10.1016/j.jpba.2017.02.002_bib0020 article-title: Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings publication-title: HIV AIDS (Auckl) – volume: 74 start-page: 1241 year: 2014 ident: 10.1016/j.jpba.2017.02.002_bib0040 article-title: Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults publication-title: Drugs doi: 10.1007/s40265-014-0256-y – year: 2011 ident: 10.1016/j.jpba.2017.02.002_bib0090 – volume: 379 start-page: 2439 year: 2012 ident: 10.1016/j.jpba.2017.02.002_bib0030 article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks publication-title: Lancet doi: 10.1016/S0140-6736(12)60917-9 – volume: 30 start-page: 662 year: 2008 ident: 10.1016/j.jpba.2017.02.002_bib0100 article-title: An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients publication-title: Ther. Drug Monit. doi: 10.1097/FTD.0b013e318189596d – volume: 48 start-page: 616 year: 2013 ident: 10.1016/j.jpba.2017.02.002_bib0055 article-title: A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients publication-title: J. Mass Spectrom. doi: 10.1002/jms.3200 – volume: 945–946 start-page: 225 year: 2013 ident: 10.1016/j.jpba.2017.02.002_bib0060 article-title: A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – volume: 848 start-page: 374 year: 2007 ident: 10.1016/j.jpba.2017.02.002_bib0105 article-title: A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2006.10.030 – volume: 11 start-page: 186 year: 2014 ident: 10.1016/j.jpba.2017.02.002_bib0010 article-title: Understanding HIV compartments and reservoirs publication-title: Curr. HIV/AIDS Rep. doi: 10.1007/s11904-014-0207-y – volume: 115 start-page: 443 year: 2015 ident: 10.1016/j.jpba.2017.02.002_bib0115 article-title: UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2015.08.004 – volume: 878 start-page: 1455 year: 2010 ident: 10.1016/j.jpba.2017.02.002_bib0075 article-title: Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2010.03.036 |
SSID | ssj0005194 |
Score | 2.3900776 |
Snippet | Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL.
[Display omitted]
•Useful... Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 223 |
SubjectTerms | Anti-HIV Agents - blood Anti-HIV Agents - chemistry Anti-Retroviral Agents - blood Anti-Retroviral Agents - chemistry Antiretrovirals Chromatography, High Pressure Liquid - methods Cobicistat - blood Cobicistat - chemistry HAART Heterocyclic Compounds, 3-Ring - blood Heterocyclic Compounds, 3-Ring - chemistry Humans Limit of Detection Liquid chromatography Protein precipitation Quinolones - blood Quinolones - chemistry Reproducibility of Results Reverse phase Rilpivirine - blood Rilpivirine - chemistry Ritonavir - blood Ritonavir - chemistry Tandem mass spectrometry Tandem Mass Spectrometry - methods |
Title | UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma |
URI | https://dx.doi.org/10.1016/j.jpba.2017.02.002 https://www.ncbi.nlm.nih.gov/pubmed/28219799 https://www.proquest.com/docview/1870648800 |
Volume | 138 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV29btswECaCdOlS9L9um4AFiiy1alOSRWkMjAbujwMDjoFsBElRBQNXViW5QJYi75A3zNDn6B0pJW2BZOhI-kgR5un4nXj3HSFvk2hcpAWTgebKgIOCl4ShToLUKPDGeKa4C6KZHyezVfzpdHK6Q6Z9LgyGVXa239t0Z627nlH3b44qa0dLUE7GETEkEYsnEXKCxjFHLX__848wD-aKIaJwgNJd4oyP8TqrFHIPMe55O8PbDqfbwKc7hI4ekgcdeqSHfoGPyI4pH5ODhaefPh_Sk5tsqmZID-jihpj6_An5tVp8mV5dXM6Xo_mS-trRFEArBRBIG4uxhbI0m21Dv2-lDyJy-0Y3BYjUxlDA4BR_qU2LnyJqWEteb7_Cs3JUYSSegN4hNesftm_BgJzWdl1ZaACmHboOl_gFs9q6BU_630klJnw1tFrDWvRGWY0ot-1mArTq5gX_AFkeGmpL6koNgrxsvsmnZHX04WQ6C7o6D4GOw7ANEpNkMk4zA2AzYwYwS65g-zMpwT01SJiXFEUuwTUE75HlPJWJAd86VUmspYmL6BnZLTeleUEoyyNtikKlHOxMrHQqweXSPNWGZxPJ9ICwfoOF7kjQsRbHWvTRbmcClUKgUohxKEApBuTd9ZjKU4DcKT3p9Ub8pcgCzqg7x73plUzAG47XNn7LBcOraLSz4wF57rXveh3gMDO8mH35n099Re5jK3B0tK_JbltvzR6grFbtu9don9w7_Ph5dvwbHrcumg |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECVS59Beiu51urFAkUst2NSuY2A0cBrbMGAbyI0gKSpQ4MqqJAfIrf_QP-yh39EZUorRAsmhR1EkRYgj8j1x5g0hn0JvlMUZE46KpAaCgoeErgqdWEtgY1EiI-NEM5uHk7X_9SK4OCDjLhYG3Srbtd-u6Wa1bkuG7dsclnk-XIJxsggRQ-gxP_D8B-QQ1amCHjk8OTufzPeeHszkQ8T6DjZoY2esm9dVKVF-iEVWutO9a3-6C3-afej0CXncAkh6Ysf4lBzo4hk5XlgF6psBXe0DquoBPaaLvTb1zXPye72Yjn_9-DlbDmdLatNHU8CtFHAgrXN0LxSF3u5q-n0nrB-RmTq6zaBKpTUFGE7xTqUb_BtRwVjSancJz0rRilF7AkoHVG-u8-4KGqS0yjdlDhcAawemwMR-Qa951QCZ_rdTgTFfNS03MBa1lblCoNu0PQFgNf0CRUChh5rmBTXZBqG-qL-JF2R9-mU1njhtqgdH-a7bOKEOE-HHiQa8mTANsCWVYAGJEMBQNWrmhVmWCmCHQCBZGsUi1ECvYxn6Smg_816SXrEt9GtCWeopnWUyjmCp8aWKBbAuFcVKR0kgmOoT1k0wV60OOqbj2PDO4e2Ko1FwNAo-cjkYRZ98vm1TWhWQe2sHnd3wv2yZwzZ1b7uPnZFx-Mjx5MZOOWd4Go1L7ahPXlnrux0HcGaGZ7NH__nUD-ThZDWb8unZ_PwNeYR3HKNO-5b0mmqn3wHoauT79qP6A09MMUs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=UPLC%E2%80%93MS%2FMS+method+for+the+simultaneous+quantification+of+three+new+antiretroviral+drugs%2C+dolutegravir%2C+elvitegravir+and+rilpivirine%2C+and+other+thirteen+antiretroviral+agents+plus+cobicistat+and+ritonavir+boosters+in+human+plasma&rft.jtitle=Journal+of+pharmaceutical+and+biomedical+analysis&rft.au=Simiele%2C+Marco&rft.au=Ariaudo%2C+Alessandra&rft.au=De+Nicol%C3%B2%2C+Amedeo&rft.au=Favata%2C+Fabio&rft.date=2017-05-10&rft.pub=Elsevier+B.V&rft.issn=0731-7085&rft.eissn=1873-264X&rft.volume=138&rft.spage=223&rft.epage=230&rft_id=info:doi/10.1016%2Fj.jpba.2017.02.002&rft.externalDocID=S0731708516314534 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0731-7085&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0731-7085&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0731-7085&client=summon |